JP2007508011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508011A5 JP2007508011A5 JP2006534031A JP2006534031A JP2007508011A5 JP 2007508011 A5 JP2007508011 A5 JP 2007508011A5 JP 2006534031 A JP2006534031 A JP 2006534031A JP 2006534031 A JP2006534031 A JP 2006534031A JP 2007508011 A5 JP2007508011 A5 JP 2007508011A5
- Authority
- JP
- Japan
- Prior art keywords
- core mimetibody
- polypeptide
- hinge core
- nucleic acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 12
- 108060003951 Immunoglobulin Proteins 0.000 claims 9
- 102000018358 immunoglobulin Human genes 0.000 claims 9
- 210000003403 autonomic nervous system Anatomy 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000000975 bioactive effect Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007914 intraventricular administration Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000010836 blood and blood product Substances 0.000 claims 2
- 229940125691 blood product Drugs 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003221 ear drop Substances 0.000 claims 2
- 229940047652 ear drops Drugs 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 238000007919 intrasynovial administration Methods 0.000 claims 2
- 229940100662 nasal drops Drugs 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000000409 cytokine receptor agonist Substances 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- -1 hormonal drugs Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50723603P | 2003-09-30 | 2003-09-30 | |
| PCT/US2004/031855 WO2005044807A2 (en) | 2003-09-30 | 2004-09-29 | Benzoimidazole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508011A JP2007508011A (ja) | 2007-04-05 |
| JP2007508011A5 true JP2007508011A5 (enExample) | 2007-11-22 |
Family
ID=38952593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534031A Pending JP2007508011A (ja) | 2003-09-30 | 2004-09-29 | ヒトヒンジコアミメティボディ、組成物、方法および用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US7432378B2 (enExample) |
| EP (1) | EP1673348B1 (enExample) |
| JP (1) | JP2007508011A (enExample) |
| KR (1) | KR20060097024A (enExample) |
| CN (1) | CN1886380B (enExample) |
| AR (1) | AR045955A1 (enExample) |
| AT (1) | ATE427303T1 (enExample) |
| AU (1) | AU2004286933B2 (enExample) |
| BR (1) | BRPI0414918A (enExample) |
| CA (1) | CA2540704A1 (enExample) |
| DE (1) | DE602004020364D1 (enExample) |
| ES (1) | ES2323178T3 (enExample) |
| HR (1) | HRP20060126A2 (enExample) |
| IL (1) | IL174677A0 (enExample) |
| NO (1) | NO20061950L (enExample) |
| NZ (1) | NZ546259A (enExample) |
| PT (1) | PT1673348E (enExample) |
| RU (1) | RU2006110561A (enExample) |
| TW (1) | TW200526637A (enExample) |
| WO (1) | WO2005044807A2 (enExample) |
| ZA (1) | ZA200603411B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045955A1 (es) * | 2003-09-30 | 2005-11-16 | Janssen Pharmaceutica Nv | Compuestos benzoimidazolicos |
| JP5162236B2 (ja) | 2004-03-25 | 2013-03-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物 |
| CA2572218C (en) | 2004-06-30 | 2013-06-11 | Janssen Pharmaceutica, N.V. | Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
| CN101248051B (zh) | 2005-05-26 | 2013-07-17 | 泰博特克药品有限公司 | 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法 |
| AU2006264649A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| EP1954287B2 (en) † | 2005-10-31 | 2016-02-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| EP1961745A1 (en) * | 2005-12-12 | 2008-08-27 | Ono Pharmaceutical Co., Ltd. | Bicyclic heterocyclic compound |
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| AU2007235577B2 (en) * | 2006-03-31 | 2011-09-15 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor |
| WO2007120690A2 (en) * | 2006-04-10 | 2007-10-25 | Janssen Pharmaceutica N.V. | Combination histamine h1r and h4r antagonist therapy for treating pruritus |
| FR2903311B1 (fr) * | 2006-07-10 | 2012-06-15 | Centre Nat Rech Scient | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| EP2077263A1 (en) | 2008-01-02 | 2009-07-08 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Quinazolines and related heterocyclic compounds and their therapeutic use |
| UA100567C2 (ru) * | 2008-06-12 | 2013-01-10 | Янссен Фармацевтика Нв | Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| EA020090B1 (ru) * | 2008-06-30 | 2014-08-29 | Янссен Фармацевтика Нв | Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного |
| BRPI0919816A2 (pt) * | 2008-09-26 | 2019-09-24 | Eisai R&D Man Co Ltd | uso compostos benzoxazólicos no tratamento de malária |
| US8354400B2 (en) | 2008-09-26 | 2013-01-15 | Eisai R&D Co., Ltd. | Benzoxazole compounds and methods of use |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| IT1395137B1 (it) * | 2009-08-05 | 2012-09-05 | Spider Biotech S R L | Nuovi peptidi antipatogeni |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| EP2447263A1 (en) * | 2010-09-27 | 2012-05-02 | Bioprojet | Benzazole derivatives as histamine H4 receptor ligands |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| DE102011122420B4 (de) | 2011-12-24 | 2016-07-28 | Volkswagen Aktiengesellschaft | Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System |
| WO2013164790A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| EP2671870A1 (en) | 2012-06-05 | 2013-12-11 | Bioprojet | Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications |
| HUE039713T2 (hu) | 2012-06-08 | 2019-02-28 | Sensorion | H4 receptor inhibitorok tinnitus kezelésére |
| JO3516B1 (ar) | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
| US11311013B2 (en) * | 2018-05-22 | 2022-04-26 | Nihon Nohyaku Co., Ltd. | Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2587029B1 (fr) * | 1985-09-11 | 1987-10-30 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| US6184235B1 (en) * | 1996-08-14 | 2001-02-06 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| TR200101239T2 (tr) | 1998-11-03 | 2001-11-21 | Basf Aktiengesellschaft | İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
| AR045955A1 (es) * | 2003-09-30 | 2005-11-16 | Janssen Pharmaceutica Nv | Compuestos benzoimidazolicos |
-
2004
- 2004-09-29 AR ARP040103534A patent/AR045955A1/es not_active Application Discontinuation
- 2004-09-29 WO PCT/US2004/031855 patent/WO2005044807A2/en not_active Ceased
- 2004-09-29 DE DE602004020364T patent/DE602004020364D1/de not_active Expired - Lifetime
- 2004-09-29 ES ES04816894T patent/ES2323178T3/es not_active Expired - Lifetime
- 2004-09-29 JP JP2006534031A patent/JP2007508011A/ja active Pending
- 2004-09-29 HR HR20060126A patent/HRP20060126A2/xx not_active Application Discontinuation
- 2004-09-29 KR KR1020067008435A patent/KR20060097024A/ko not_active Withdrawn
- 2004-09-29 CN CN2004800354157A patent/CN1886380B/zh not_active Expired - Fee Related
- 2004-09-29 RU RU2006110561/04A patent/RU2006110561A/ru not_active Application Discontinuation
- 2004-09-29 AU AU2004286933A patent/AU2004286933B2/en not_active Ceased
- 2004-09-29 CA CA002540704A patent/CA2540704A1/en not_active Abandoned
- 2004-09-29 NZ NZ546259A patent/NZ546259A/en unknown
- 2004-09-29 US US10/952,989 patent/US7432378B2/en not_active Expired - Lifetime
- 2004-09-29 AT AT04816894T patent/ATE427303T1/de not_active IP Right Cessation
- 2004-09-29 TW TW093129453A patent/TW200526637A/zh unknown
- 2004-09-29 PT PT04816894T patent/PT1673348E/pt unknown
- 2004-09-29 EP EP04816894A patent/EP1673348B1/en not_active Expired - Lifetime
- 2004-09-29 BR BRPI0414918-1A patent/BRPI0414918A/pt not_active IP Right Cessation
-
2006
- 2006-03-30 IL IL174677A patent/IL174677A0/en unknown
- 2006-04-28 ZA ZA200603411A patent/ZA200603411B/en unknown
- 2006-05-02 NO NO20061950A patent/NO20061950L/no not_active Application Discontinuation
-
2008
- 2008-08-26 US US12/229,779 patent/US20090270611A1/en not_active Abandoned
- 2008-08-26 US US12/229,891 patent/US20090281307A1/en not_active Abandoned
- 2008-08-26 US US12/229,892 patent/US7662966B2/en not_active Expired - Lifetime
- 2008-08-26 US US12/229,888 patent/US7705143B2/en not_active Expired - Lifetime
- 2008-08-26 US US12/229,781 patent/US7723526B2/en not_active Expired - Lifetime
- 2008-08-26 US US12/229,886 patent/US7723527B2/en not_active Expired - Lifetime
- 2008-08-26 US US12/229,882 patent/US7705149B2/en not_active Expired - Lifetime
- 2008-08-26 US US12/229,890 patent/US7723359B2/en not_active Expired - Lifetime
- 2008-10-23 US US12/257,362 patent/US20090247508A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512522A5 (enExample) | ||
| KR102422860B1 (ko) | 항체-약물 콘주게이트의 신규 제조 방법 | |
| JP2024161402A (ja) | 抗ｔｌ１ａモノクローナル抗体の中和 | |
| ES2384110T3 (es) | Anticuerpo anti-PLGF novedoso | |
| ES2401536T3 (es) | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden | |
| EP2291659B1 (en) | Chimeric small molecules for the recruitment of antibodies to cancer cells | |
| BR112020000766A2 (pt) | anticorpos anti-cd166 e seus usos | |
| KR101309948B1 (ko) | 혈관 신생 억제 화합물 | |
| ES2872964T3 (es) | Inmunoconjugado de IL-12 | |
| RU2714933C2 (ru) | Конъюгаты var2csa-лекарственное средство | |
| ES2759530T3 (es) | Composición farmacéutica que contiene derivados de glutarimida, y la aplicación de la misma para el tratamiento de enfermedades eosinofílicas | |
| ME02185B (me) | Anti-il-6 antitela, preparati, postupci pripreme i upotrebe | |
| CA2609349A1 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
| JP2019059730A (ja) | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン | |
| JP2008525477A5 (enExample) | ||
| JP2005533001A5 (enExample) | ||
| JP2012524030A (ja) | Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療 | |
| WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
| US20260008848A1 (en) | Anti-nectin-4 antibody, and antibody-drug conjugate and use thereof | |
| US20170014524A1 (en) | Auristatin-antibody conjugates and uses thereof | |
| JP2010534664A5 (enExample) | ||
| CN118019550A (zh) | 预防、缓解或治疗黏膜黏连的药物及其应用 | |
| CN115698059A (zh) | 使用抗bet v 1抗体治疗过敏的方法 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| US20250171526A1 (en) | Treatment for Facioscapulohumeral Muscular Dystrophy (FSHD) |